PreludeDx develops molecular diagnostics and personalized medicine specifically for early-stage breast cancer, aiming to enhance decision-making for patients and physicians. Founded in 2009 and based in Laguna Hills, California, the company leverages technology licensed from the University of California San Francisco to create innovative tools that influence treatment options. One of its primary offerings is The DCISionRT, a test that predicts the potential benefit of radiation therapy for patients with ductal carcinoma in situ. By incorporating advancements in molecular biology, artificial intelligence, and machine learning, PreludeDx seeks to improve patient outcomes and reduce healthcare costs associated with breast cancer treatment.
Magnolia Medical Technologies, Inc. is a Seattle-based company that specializes in the development and manufacturing of medical devices aimed at enhancing the accuracy of diagnostic blood culture tests. Its flagship product, SteriPath, is a vacuum-assisted blood collection system designed to divert contaminants from the initial blood sample, thereby reducing the incidence of blood culture sample contamination. The company markets its products through distributors across the United States and has built a robust intellectual property portfolio, consisting of over 70 issued patents and more than 50 pending applications. Founded in 2011, Magnolia Medical Technologies is committed to improving diagnostic specimen quality and increasing the accuracy of critical laboratory tests.
Sonde Health is a digital medicine company that focuses on voice-based technologies for monitoring and diagnosing mental and respiratory health. The company's platform analyzes subtle changes in a person's voice, captured through mobile devices, to generate various health measurements related to brain, muscle, and respiratory functions. This technology enables users to track their health over time and detect early signs of potential health issues. By leveraging voice analysis, Sonde aims to transform traditional approaches to health monitoring and diagnosis, providing a convenient and innovative way to manage personal health.
Magnolia Medical Technologies, Inc. is a Seattle-based company that specializes in the development and manufacturing of medical devices aimed at enhancing the accuracy of diagnostic blood culture tests. Its flagship product, SteriPath, is a vacuum-assisted blood collection system designed to divert contaminants from the initial blood sample, thereby reducing the incidence of blood culture sample contamination. The company markets its products through distributors across the United States and has built a robust intellectual property portfolio, consisting of over 70 issued patents and more than 50 pending applications. Founded in 2011, Magnolia Medical Technologies is committed to improving diagnostic specimen quality and increasing the accuracy of critical laboratory tests.
EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company is known for its Transoral Incisionless Fundoplication (TIF®) procedure, which provides a minimally invasive alternative to traditional surgical methods by allowing treatment without external incisions. Key products include the EsophyX technology, which facilitates transoral reconstructive surgery, and the SerosaFuse Fasteners, designed for secure tissue attachment. Additionally, EndoGastric Solutions offers training courses for surgeons and a range of consultative support services. Founded in 2002 and headquartered in Redmond, Washington, the company also has an office in San Mateo, California.
Akili Interactive Labs, Inc. is a digital medicine company based in Boston, Massachusetts, that develops innovative platform technology to enhance cognitive abilities through video game-like experiences. Incorporated in 2011, the company focuses on creating clinically validated cognitive therapeutics, assessments, and diagnostics that can be prescribed and monitored by physicians remotely. Akili's cognitive engine supports multiple clinical game versions designed for patient engagement and remote data capture. Its proprietary adaptive mechanics allow the software to personalize to each patient's ability level automatically, without requiring clinician input. This approach aims to provide a cost-effective alternative to traditional medical treatments, making advanced cognitive therapies accessible to patients regardless of their location.
Cardiva Medical, Inc. is a medical device company that specializes in vascular access management products aimed at facilitating the body's natural healing process after percutaneous catheterization procedures. Its product lineup includes VASCADE VCS, a bioabsorbable femoral access closure system that promotes rapid hemostasis and reduces complications. Additionally, Cardiva offers the Catalyst manual compression assistance device, which supports temporary hemostasis and improves coagulation for patients needing manual compression. The company also manufactures VASCADE MVP, a vascular closure system for multi-site venous closure during electrophysiology procedures such as cardiac ablation. Founded in 2002 and headquartered in Santa Clara, California, Cardiva Medical serves physicians and cardiac centers across the United States.
Dune Medical Devices, established in 2002, specializes in tissue characterization technology aimed at enhancing cancer detection during surgical procedures. The company has developed the MarginProbe™ System, which utilizes radiofrequency spectroscopy to provide real-time assessments of excised tissue, helping surgeons determine whether cancerous margins have been adequately removed. This innovative approach addresses a critical concern for oncological surgeons, particularly in breast cancer treatment, by enabling them to make informed decisions during surgery, thus potentially reducing the need for reoperations. In a study involving 300 breast cancer patients in Israel, the use of the MarginProbe System resulted in a 56% reduction in reoperation rates compared to standard practices. Dune Medical Devices' solutions focus on improving the cancer care experience by consistently differentiating between cancerous and healthy tissue, ultimately aiming to enhance patient outcomes.
Magnolia Medical Technologies, Inc. is a Seattle-based company that specializes in the development and manufacturing of medical devices aimed at enhancing the accuracy of diagnostic blood culture tests. Its flagship product, SteriPath, is a vacuum-assisted blood collection system designed to divert contaminants from the initial blood sample, thereby reducing the incidence of blood culture sample contamination. The company markets its products through distributors across the United States and has built a robust intellectual property portfolio, consisting of over 70 issued patents and more than 50 pending applications. Founded in 2011, Magnolia Medical Technologies is committed to improving diagnostic specimen quality and increasing the accuracy of critical laboratory tests.
Cardiva Medical, Inc. is a medical device company that specializes in vascular access management products aimed at facilitating the body's natural healing process after percutaneous catheterization procedures. Its product lineup includes VASCADE VCS, a bioabsorbable femoral access closure system that promotes rapid hemostasis and reduces complications. Additionally, Cardiva offers the Catalyst manual compression assistance device, which supports temporary hemostasis and improves coagulation for patients needing manual compression. The company also manufactures VASCADE MVP, a vascular closure system for multi-site venous closure during electrophysiology procedures such as cardiac ablation. Founded in 2002 and headquartered in Santa Clara, California, Cardiva Medical serves physicians and cardiac centers across the United States.
Akili Interactive Labs, Inc. is a digital medicine company based in Boston, Massachusetts, that develops innovative platform technology to enhance cognitive abilities through video game-like experiences. Incorporated in 2011, the company focuses on creating clinically validated cognitive therapeutics, assessments, and diagnostics that can be prescribed and monitored by physicians remotely. Akili's cognitive engine supports multiple clinical game versions designed for patient engagement and remote data capture. Its proprietary adaptive mechanics allow the software to personalize to each patient's ability level automatically, without requiring clinician input. This approach aims to provide a cost-effective alternative to traditional medical treatments, making advanced cognitive therapies accessible to patients regardless of their location.
BioTheranostics, Inc. is a commercial-stage molecular diagnostics company focused on developing and providing proprietary diagnostic tests that aid physicians in making informed decisions regarding cancer treatment. The company offers several key products, including the Breast Cancer Index, which assists oncologists in determining the appropriateness of extended endocrine therapy for patients with estrogen receptor-positive breast cancer. Additionally, CancerTYPE ID delivers critical genomic information for the diagnosis and management of metastatic cancer, while the bioT3 metastatic cancer solution integrates precise molecular diagnosis with extensive biomarker data to enhance treatment options for metastatic cancer patients. Founded in 1996 and headquartered in San Diego, California, BioTheranostics aims to support personalized medicine by ensuring that every patient receives a tailored care plan.
Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacturing of side branch stent systems designed to treat coronary bifurcation lesions in patients with cardiovascular diseases. Founded in 2003, the company provides its innovative Tryton Side Branch Stent System, which targets atherosclerotic lesions at bifurcation sites. Tryton Medical distributes its products through a global network of distributors and also addresses investigational needs within the United States. The company's offerings are available in several countries, including Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom.
Cardiva Medical, Inc. is a medical device company that specializes in vascular access management products aimed at facilitating the body's natural healing process after percutaneous catheterization procedures. Its product lineup includes VASCADE VCS, a bioabsorbable femoral access closure system that promotes rapid hemostasis and reduces complications. Additionally, Cardiva offers the Catalyst manual compression assistance device, which supports temporary hemostasis and improves coagulation for patients needing manual compression. The company also manufactures VASCADE MVP, a vascular closure system for multi-site venous closure during electrophysiology procedures such as cardiac ablation. Founded in 2002 and headquartered in Santa Clara, California, Cardiva Medical serves physicians and cardiac centers across the United States.
Dune Medical Devices, established in 2002, specializes in tissue characterization technology aimed at enhancing cancer detection during surgical procedures. The company has developed the MarginProbe™ System, which utilizes radiofrequency spectroscopy to provide real-time assessments of excised tissue, helping surgeons determine whether cancerous margins have been adequately removed. This innovative approach addresses a critical concern for oncological surgeons, particularly in breast cancer treatment, by enabling them to make informed decisions during surgery, thus potentially reducing the need for reoperations. In a study involving 300 breast cancer patients in Israel, the use of the MarginProbe System resulted in a 56% reduction in reoperation rates compared to standard practices. Dune Medical Devices' solutions focus on improving the cancer care experience by consistently differentiating between cancerous and healthy tissue, ultimately aiming to enhance patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.